Regarding safety, cemiplimab’s adverse event (AE) profile was manageable and consistent with those established among PD-1 ...

The FDA designates ofirnoflast as an orphan drug, highlighting its innovative approach to treating myelodysplastic syndromes ...

At the molecular level, transcriptomic profiling of a single nucleus RNA-seq dataset of renal epithelial cells revealed ...

A recent clinical trial found that transplantation in lower-risk myelodysplastic syndrome (MDS) patients with high-risk ...

The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...

To understand treatment patterns and preferences, a series of expert-led Case-Based Roundtable events were conducted over the ...

Patients enrolled had NET liver metastases of any grade or origin that were progressive, symptomatic, or represented a high ...

The US FDA has approved the supplemental new drug application (sNDA) for revumenib (Revuforj) in the treatment of relapsed or ...

MT-125, a dual small-molecule inhibitor, received FDA fast track designation for glioblastoma, facilitating expedited drug ...

Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved ...

A panelist discusses how early relapse and prognostic indicators shape second-line therapy selection and emerging treatment ...

The US FDA has granted fast track designation to the novel amanitin-based antibody-drug conjugate (ADC) pamlectabart ...